ClinicalTrials.gg
CompletedNCT03734354Updated Nov 1, 2023

The Pharmacokinetics, Tolerability and Safety of Brexpiprazole in Healthy Chinese Subjects

A Phase 1 interventional study of Brexpiprazole in Health, sponsored by Otsuka Beijing Research Institute. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-11-01.

Sponsored by Otsuka Beijing Research Institute (part of Otsuka Holdings Co., Ltd.) · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

This study is a single-center, open-label study evaluating the pharmacokinetics, tolerability and safety of single dose oral brexpiprazole tablets in healthy Chinese subjects. A total of 30 healthy adult subjects are to be enrolled into the study. Three dose groups will be set up, with about 10 subjects in each dose group. Subjects will enter 1 mg, 2 mg and 4 mg dose groups in sequence.

Read the detailed description

A total of 30 healthy adult subjects are to be enrolled into the study. Three dose groups will be set up, with about 10 subjects in each dose group. Subjects will enter 1 mg, 2 mg and 4 mg dose groups in sequence.

After the clinical trial responsible physicians obtain the informed consent forms from subjects, the subjects will be screened 14 days to 1 days prior to taking the study drug (D-14\~D-1).

One day prior to dosing in each group (D-1), the included subjects are hospitalized On the next day (D1), after completed the hospitalization inspection, eligible subjects will be assigned subject numbers to start with the first dose, complete corresponding examination, stay in hospital for observation and be discharged on Day 4 of medication. On days 6, 8, 10, 12 blood samples are collected and safety evaluation will be performed. Telephone follow-up will be performed on day Day31.

Blood samples are collected to determine and evaluate blood concentrations of Brexpiprazole and its main metabolite DM-3411 before dosing, and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 168, 216, 264 hours after dosing, with 18 sampling points in total.

02

Conditions studied

  • Health
03

In context

Lead sponsor

Otsuka Beijing Research Institute is the lead sponsor of 36 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    1. Sign the form
  • 2.At the age of 18\~45 years old (including upper and lower limits) when signing the informed consent form.
  • 3.Body weight of not less than 50kg, 19 \~ 24kg/m2 (including the upper and lower limits) [ body mass index (BMI) = body weight (kg) / height2 (m2)].

Exclusion criteria

Exclusion Criteria:

    1. Participated in any interventional clinical trial within 12 weeks prior to enrollment.
  • 2.Drug abuse in the past 2 years or a history of abuse
  • 3.Drinking alcohol more than 2 unit per day (1 unit= 360 ml beer , or 45 ml 4.0% alcohol, or 150 ml liquor, or 50 ml wine ) 6 months before the screening, or subjects can not stop drinking during the hospitalization
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    1 mg dosing group

    Dosing group 1, single/oral/with fasting, Brexpiprazole 1.0 mg, 1 tablets

    Drug: Brexpiprazole

  • Experimental
    2 mg dosing group

    Dosing group 2, single/oral/with fasting, Brexpiprazole 1.0 mg, 2 tablets

    Drug: Brexpiprazole

  • Experimental
    4 mg dosing group

    Dosing group 3, single/oral/with fasting, Brexpiprazole 1.0 mg, 4 tablets

    Drug: Brexpiprazole

Interventions

  • Brexpiprazole , single/oral/with fasting

    Also known as: Brex

06

What researchers measure

Primary outcomes

  1. The peak concentration (Cmax) after the first administration

    The peak concentration (Cmax) of Brexipiprazole and the metabolite DM-3411 after administration

    Time frame: 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 168, 216, 264 hours

  2. The peak time (Tmax) after the first administration

    The peak-time of Brexipiprazole and the metabolite DM-3411 on the first day after administration are calculated.

    Time frame: 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 168, 216, 264 hours

  3. Area under the plasma concentration-time curve (AUC0-264h)

    The area under the plasma concentration-time curve of Brexipiprazole after administration are calculated.

    Time frame: 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 168, 216, 264 hours

  4. Half time after the first administration

    The half time of Brexipiprazole after administration are calculated.

    Time frame: 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 168, 216, 264 hours

  5. Apparent clearance after the first administration

    To assess the apparent clearance after administration (CL/F) of Brexipiprazole after the first administration

    Time frame: 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 168, 216, 264 hours

  6. Proportional dose-response relationship between pharmacokinetic parameters Cmax and AUC of OPC-34712

    To assess the Proportional dose-response relationship between pharmacokinetic parameters Cmax and AUC of OPC-34712

    Time frame: 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 168, 216, 264 hours

Secondary outcomes

  1. Blood pressure

    To seeess blood pressure after administration of brexpiprazole

    Time frame: 0, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 168, 216, 264 hours

  2. Heart rate

    To seeess heart rate after administration of brexpiprazole

    Time frame: 0, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 168, 216, 264 hours

  3. Body weight

    To seeess Body weight after administration of brexpiprazole

    Time frame: 1, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 168, 216, 264 hours

  4. 12-lead ECG

    To seeess 12-lead ECG after administration of brexpiprazole

    Time frame: 3, 6, 24, 72, 96, 120, 264 hours

  5. Blood biochemistry

    To seeess blood biochemistry after administration of brexpiprazole

    Time frame: 24, 96, 264 hours

  6. Blood routine

    To seeess blood routine after administration of brexpiprazole

    Time frame: 24, 96, 264 hours

  7. urinary routine

    To seeess urinary routine after administration of brexpiprazole

    Time frame: 24, 96, 264 hours

07

Study locations

1 site
  • Beijing Anding Hospital of Capital Medical University
    Beijing, Beijing 100088, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2019 to primary completion in May 2020, 13 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2018
First posted
Nov 7, 2018
StartActual
Apr 7, 2019
Primary completionActual
May 18, 2020
CompletionActual
May 18, 2020
Last update
Nov 1, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 1, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03734354
Responsible party
Sponsor
First posted
Nov 7, 2018
Start date
Apr 7, 2019
Primary completion
May 18, 2020
Completion
May 18, 2020
Last update
Nov 1, 2023

Study contacts

Tao Jiang, Master
principal investigator · Beijing Anding Hospital of Capital Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brexpiprazole

Start the discussion